Efficacy of Pamidronate in Complex Regional Pain Syndrome Type I

Robinson, John N.; Sandom, Jenny; Chapman, Peter T.

doi:10.1111/j.1526-4637.2004.04038.x

Cited by 136 publications

(90 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The review did not apply up to date systematic review methodology, did not search all relevant electronic databases and was incomplete in respect to quality assessment. Since electronic searches were limited to 2003 they missed two studies (Manicourt et al 2004;Robinson et al 2004) out of which one study contributed data to our meta-analysis (Manicourt et al 2004). On the other hand, Chauvineau and colleagues included two studies that we excluded from our analysis.…”

Section: Results In Light Of Existing Evidencementioning

confidence: 99%

“…Full text assessment resulted in exclusion of 12 additional studies. In total four trials were included in this review (Adami et al 1997;Varenna et al 2000;Manicourt et al 2004;Robinson et al 2004). (For study selection details please see figure 1).…”

Section: Resultsmentioning

confidence: 99%

“…Due to the variability in respect to interventions, enrolment criteria, control treatments, duration of follow-up visits and outcome measures, only two out of four studies were considered clinically comparable regarding pain intensity (VAS) after 4 and 12 weeks (Manicourt et al 2004;Robinson et al 2004). Statistical pooling showed a weighted average of -22.4 after 4 weeks and -21.6 after 12 weeks on a scale of 100.…”

Section: Evidence Of Effectivenessmentioning

confidence: 99%

“…Due to different measures of range of motion, statistical pooling was not possible (goniometer (Manicourt et al 2004) vs. arbitrary score (Adami et al 1997). One study showed a significant improvement of physical function in the treatment group by assessing SF-36 after 1 and 3 months (Robinson et al 2004). None of the studies considered measuring the aspect of quality of life.…”

Section: Evidence Of Improvement Of Quality Of Life and Functionmentioning

confidence: 99%

“…The participants were treated either with oral (n=1) (Manicourt et al 2004) or intravenous administration (n=3) (Adami et al 1997;Varenna et al 2000;Robinson et al 2004) of a biphosphonate compound. Alendronate was used in two studies, pamidronate (Robinson et al 2004) and clondronate (Varenna et al 2000) were administered once. Side effects were evaluated in all 4 studies and were rare.…”

Section: Description Of Studiesmentioning

confidence: 99%

See 4 more Smart Citations

Biphosphonates for the therapy of complex regional pain syndrome I – Systematic review

Brunner

Schmid

Kissling

et al. 2009

European Journal of Pain

View full text Add to dashboard Cite

Objectives: Several studies found that biphosphonates counteract locally increased bone resorption and associated pain in patients with complex regional pain syndrome I (CRPS I). We performed a systematic review of all randomised controlled trials to assess the benefit of biphosphonates in the treatment of CRPS I patients with bone loss. Data sources: We searched Medline, Embase (April 2007) and the Cochrane Library and screened bliographies of included studies. Review methods: We selected randomised trials comparing biphosphonates with placebo, with the goal of improving pain, function and quality of life in patients with CRPS I. Two reviewers independently assessed trial eligibility and quality, and extracted data. Where data were incomplete or unclear, conflicts were resolved with discussion and/or trial authors were contacted for further details. We calculated the study size weighted pooled mean reduction of pain intensity (measured with a visual analogue scale (VAS)). Results: Four trials of moderate quality fulfilled our inclusion criteria. In respect to function and quality of life there was a trend in favour of biphosphonates but differences in outcome assessment impeded pooling of results. Two trials provided sufficient data to pool pain outcomes. Biphosphonates reduced pain intensity by 22.4 and 21.6mm on a VAS after 4 and 12 weeks of follow‐up. Data on adverse effects were scarce. Conclusions: The very limited data reviewed showed that bisphosphonates have the potential to reduce pain associated with bone loss in patients with CRPS I. However, at present there is not sufficient evidence to recommend their use in practice.

show abstract

Section: Results In Light Of Existing Evidencementioning

confidence: 99%